Is there a program that can estimate the heterozygosity of a sample using the kmer frequency distribution of the raw reads? I have whole genome, Illumina data (100bp PE reads, from 300bp fragments). The kmer frequency plot has a clear bimodal distribution, so I can get a rough estimate by eyeballing the areas under the curves for the two peaks. I am hoping to find a more robust method and more automated since I have over 100 samples.
-
-
push
Actually I have no responds neither, I am afraid.
I am just asking myself the same question and wondered whether you were able to solve that question ? -
Perhaps you want to look into Ka/Ks estimation.Comment
-
I just came across this paper on arxiv "Estimation of genomic characteristics by analyzing k-mer frequency in de novo genome projects"
I have not tried their tool though! It is available at ftp://ftp.genomics.org.cn/pub/gce/
Best,
~wormSeeq.Comment
-
Hmmm, I wrote a program that does this. Well, two, actually. Their usage is about the same.
khist.sh in=reads.fq khist=khist.txt peaks=peaks.txt
or
kmercountexact.sh in=reads.fq khist=khist.txt peaks=peaks.txt
The first uses approximate counts, while the second uses exact counts (and thus potentially more memory). The peaks file header contains estimates of genome size and heterozygousity. You can also add the flag "ploidy=2" for diploid organisms, so that it won't need to autodetect the ploidy (and thus potentially make a mistake).
These are both distributed with BBTools.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment